688428 诺诚健华
已收盘 12-05 15:00:00
资讯
新帖
简况
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
证券之星 · 12-04 22:20
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
证券日报 · 11-29
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
每日经济新闻 · 11-28
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
美股速递 · 11-28
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元
证券之星 · 11-23
每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元
每周股票复盘：诺诚健华（688428）Q3营收增38.09%
证券之星 · 11-16
每周股票复盘：诺诚健华（688428）Q3营收增38.09%
图解诺诚健华三季报：第三季度单季净利润同比下降152.94%
证券之星 · 11-13
图解诺诚健华三季报：第三季度单季净利润同比下降152.94%
诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元
智通财经 · 11-13
诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元
每周股票复盘：诺诚健华（688428）购回80万股份
证券之星 · 11-09
每周股票复盘：诺诚健华（688428）购回80万股份
诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%
证券之星 · 11-05
诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%
每周股票复盘：诺诚健华（688428）将发布Q3业绩
证券之星 · 11-02
每周股票复盘：诺诚健华（688428）将发布Q3业绩
每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作
证券之星 · 10-19
每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作
诺诚健华（688428）披露回购H股股份进展，10月13日股价下跌0.21%
证券之星 · 10-13
诺诚健华（688428）披露回购H股股份进展，10月13日股价下跌0.21%
每周股票复盘：诺诚健华（688428）授权Zenas获1亿美元首付
证券之星 · 10-12
每周股票复盘：诺诚健华（688428）授权Zenas获1亿美元首付
诺诚健华(09969)10月10日斥资1176.8万港元回购80万股
智通财经 · 10-10
诺诚健华(09969)10月10日斥资1176.8万港元回购80万股
诺诚健华再挫逾8% 日前宣布与Zenas就三款自免管线达成授权许可合作
智通财经 · 10-10
诺诚健华再挫逾8% 日前宣布与Zenas就三款自免管线达成授权许可合作
10月9日诺诚健华-U跌6.24%，富国精准医疗混合A基金重仓该股
证券之星 · 10-09
10月9日诺诚健华-U跌6.24%，富国精准医疗混合A基金重仓该股
诺诚健华-U跌6.24%，太平洋一个月前给出“买入”评级，目标价32.22元
证券之星 · 10-09
诺诚健华-U跌6.24%，太平洋一个月前给出“买入”评级，目标价32.22元
Zenas BioPharma Inc.新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计2026年启动一期临床试验
美股速递 · 10-08
Zenas BioPharma Inc.新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计2026年启动一期临床试验
Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段
美股速递 · 10-08
Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":24.99,"timestamp":1764918000000,"preClose":24.84,"halted":0,"volume":2668316,"delay":0,"changeRate":0.006,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"已收盘","change":0.15,"latestTime":"12-05 15:00:00","open":24.88,"high":25.04,"low":24.38,"amount":65959700,"amplitude":0.0266,"askPrice":24.99,"askSize":69,"bidPrice":24.94,"bidSize":243,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.84,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":27.32,"lowLimit":22.36,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1764643952,"isCdr":false,"pbRate":6.62,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.228537,"marketValue":44098000000,"turnoverRate":0.0099,"status":0,"afterMarket":{"amount":0,"volume":0,"close":24.99,"buyVolume":0,"sellVolume":0,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":24.84},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.36,"timestamp":1764922148009,"preClose":14.44,"halted":0,"volume":4367920,"delay":0,"premium":"-47.81"},"floatMarketCap":6706000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2588880472","title":"诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880472?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:20","pubTimestamp":1764858034,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，诺诚健华报收于24.84元，较前一交易日上涨1.89%，最新总市值为438.34亿元。公司近日发布公告，披露截至2025年11月30日的证券变动月报表。公告显示，诺诚健华医药有限公司法定股本无变动，已发行股份总数保持不变。公司存在股权激励计划，包括2023年及2024年人民币股股份激励计划，部分限制性股票已失效，但本月未发生新股发行或库存股转让。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","161027","BK1161","688428","BK0239","BK1574"],"gpt_icon":0},{"id":"2587751162","title":"诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2587751162","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587751162?lang=zh_cn&edition=full","pubTime":"2025-11-29 11:36","pubTimestamp":1764387398,"startTime":"0","endTime":"0","summary":"11月28日，诺诚健华医药有限公司（以下简称“诺诚健华”）宣布，公司自主研发的新型TYK2抑制剂Soficitinib（ICP-332）治疗结节性痒疹的全球II期临床试验完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511293578279828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","688428","BK1161","BK0239","09969"],"gpt_icon":1},{"id":"2586189785","title":"诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586189785","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586189785?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:15","pubTimestamp":1764324916,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近两年是否出口欧盟国家？诺诚健华（688428.SH）11月28日在投资者互动平台表示，尊敬的投资者，您好！截至目前，公司暂无自研药品于欧盟范围内获批及销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511283577874557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511283577874557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","688428","09969","BK0239","BK1161"],"gpt_icon":0},{"id":"1169461698","title":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","url":"https://stock-news.laohu8.com/highlight/detail?id=1169461698","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169461698?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:56","pubTimestamp":1764295015,"startTime":"0","endTime":"0","summary":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2585103116","title":"每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103116","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103116?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:43","pubTimestamp":1763836991,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，诺诚健华报收于23.36元，较上周的25.34元下跌7.81%。本周，诺诚健华11月17日盘中最高价报25.42元。本周关注点来自业绩披露要点：奥布替尼2025年1-9月销售收入达10.10亿元，同比增长45.77%。来自机构调研要点：奥布替尼全球Ⅲ期试验将与Zenas分别于2025年底及2026年Q1启动。答：公司2025年1-9月总营业收入11.15亿元，同比增长59.85%，毛利率88.8%。公司已在2025年第四季度收到Zenas支付的现金首付款及500万股普通股，带来即期财务收益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2583594586","title":"每周股票复盘：诺诚健华（688428）Q3营收增38.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583594586?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:33","pubTimestamp":1763231592,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，诺诚健华报收于25.34元，较上周的23.86元上涨6.2%。本周，诺诚健华11月13日盘中最高价报25.95元。本周关注点业绩披露要点：诺诚健华2025年第三季度营收3.84亿元，同比增长38.09%。公司公告汇总诺诚健华医药有限公司2025年第三季度报告显示，本报告期营业收入383,894,221.54元，同比增长38.09%；年初至报告期末营业收入1,115,328,393.86元，同比增长59.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"gpt_icon":0},{"id":"2583569524","title":"图解诺诚健华三季报：第三季度单季净利润同比下降152.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569524","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583569524?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:02","pubTimestamp":1763031737,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华2025年三季报显示，前三季度公司主营收入11.15亿元，同比上升59.85%；归母净利润-6441.49万元，同比上升76.61%；扣非净利润-1.35亿元，同比上升49.32%；其中2025年第三季度，公司单季度主营收入3.84亿元，同比上升38.09%；单季度归母净利润-3432.35万元，同比下降152.94%；单季度扣非净利润-5307.75万元，同比下降265.85%；负债率29.88%，投资收益3652.65万元，财务费用-7494.74万元，毛利率88.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300034903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"gpt_icon":0},{"id":"2583155085","title":"诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583155085","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583155085?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:11","pubTimestamp":1763025111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元，同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收益-0.04元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2582864806","title":"每周股票复盘：诺诚健华（688428）购回80万股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864806","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582864806?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:40","pubTimestamp":1762634416,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，诺诚健华报收于23.86元，较上周的24.53元下跌2.73%。本周，诺诚健华11月3日盘中最高价报24.79元。诺诚健华当前最新总市值421.04亿元，在化学制药板块市值排名12/151，在两市A股市值排名430/5166。本周关注点公司公告汇总：诺诚健华于2025年10月10日购回800,000股股份作为库存股，价格为每股14.71港元。公司公告汇总诺诚健华医药有限公司截至2025年10月31日的证券变动月报表显示，公司法定/注册股本无变动，总额为50,000美元，每股面值0.000002美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","688428","BK1574","BK0239"],"gpt_icon":0},{"id":"2581895776","title":"诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581895776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581895776?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:28","pubTimestamp":1762352904,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，诺诚健华报收于23.88元，较前一交易日下跌1.49%，最新总市值为421.4亿元。公司近日发布公告，披露截至2025年10月31日的证券变动月报表。公告显示，诺诚健华法定/注册股本无变动，总额为50,000美元，每股面值0.000002美元。根据2023年及2024年人民币股股份激励计划，部分限制性股票失效，截至2025年10月末，累计4,531,250股及9,702,200股可能发行。2025年10月10日，公司购回800,000股股份作为库存股，价格为每股14.71港元，股东大会通过日期为2025年6月20日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09969","161027","BK1161","BK0239","688428"],"gpt_icon":0},{"id":"2580947560","title":"每周股票复盘：诺诚健华（688428）将发布Q3业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2580947560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580947560?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:57","pubTimestamp":1762023430,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，诺诚健华报收于24.53元，较上周的22.41元上涨9.46%。本周，诺诚健华10月31日盘中最高价报24.72元。诺诚健华当前最新总市值432.87亿元，在化学制药板块市值排名12/151，在两市A股市值排名411/5163。本周关注点公司公告汇总：诺诚健华将于2025年11月13日召开董事会，审议并发布截至2025年9月30日止九个月的未经审核第三季度业绩。承董事会命，诺诚健华医药有限公司，香港，2025年10月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","09969","688428","BK1161"],"gpt_icon":0},{"id":"2576464700","title":"每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2576464700","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576464700?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:06","pubTimestamp":1760814371,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，诺诚健华报收于23.75元，较上周的24.29元下跌2.22%。本周，诺诚健华10月14日盘中最高价报25.62元。本周关注点来自机构调研要点：诺诚健华与Zenas达成超20亿美元合作，获1亿美元首付款及700万普通股。交易已生效，公司收到首笔现金首付款，并获发500万股Zenas普通股，带来即期财务收益并增强现金储备。公司公告汇总诺诚健华于2025年10月10日购回800,000股普通股，每股价格14.71港元，总金额11,768,000港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","BK0239","688428","09969"],"gpt_icon":0},{"id":"2575471385","title":"诺诚健华（688428）披露回购H股股份进展，10月13日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575471385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575471385?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:19","pubTimestamp":1760347192,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘，诺诚健华报收于24.24元，较前一交易日下跌0.21%，最新总市值为427.75亿元。该等股份拟持作库存股份，不拟注销。购回股份于本交易所进行，占有关事件前已发行股份数目的0.454%。截至2025年10月10日，已发行股份总数为1,496,284,235股。购回授权决议于2025年6月20日获通过，可购回股份总数为176,088,119股，本次购回占授权当日已发行股份数目的0.0454%。购回后30天内不得发行新股或出售库存股份，暂止期至2025年11月9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300019964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","BK0239","09969"],"gpt_icon":0},{"id":"2574440457","title":"每周股票复盘：诺诚健华（688428）授权Zenas获1亿美元首付","url":"https://stock-news.laohu8.com/highlight/detail?id=2574440457","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574440457?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:54","pubTimestamp":1760205251,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，诺诚健华报收于24.29元，较上周的28.52元下跌14.83%。本周，诺诚健华10月9日盘中最高价报31.42元。本周关注点公司公告汇总：诺诚健华子公司授权奥布替尼等药物海外权益，获1亿美元首付款及潜在超20亿美元交易总额。Zenas将支付1亿美元首付款及近期里程碑款，并向公司授予700万普通股股票，总交易额潜在超过20亿美元，另加最高达百分之十几的分层特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","09969","BK1161","BK0239"],"gpt_icon":0},{"id":"2574178517","title":"诺诚健华(09969)10月10日斥资1176.8万港元回购80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574178517","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574178517?lang=zh_cn&edition=full","pubTime":"2025-10-10 19:15","pubTimestamp":1760094957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2025年10月10日，该公司斥资1176.8万港元回购80万股股份，每股回购价格为14.71港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09969","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2574110491","title":"诺诚健华再挫逾8% 日前宣布与Zenas就三款自免管线达成授权许可合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2574110491","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574110491?lang=zh_cn&edition=full","pubTime":"2025-10-10 10:58","pubTimestamp":1760065080,"startTime":"0","endTime":"0","summary":"诺诚健华(09969)再挫逾8%，该股昨日大跌超11%。截至发稿，跌8.84%，报15.15港元，成交额4.35亿港元。消息面上，诺诚健华日前公告称，全资子公司InnoCare Pharma Inc.（简称“公司”）与Zena ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251010/c671628733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2574131099","title":"10月9日诺诚健华-U跌6.24%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574131099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574131099?lang=zh_cn&edition=full","pubTime":"2025-10-09 16:38","pubTimestamp":1759999124,"startTime":"0","endTime":"0","summary":"证券之星消息，10月9日诺诚健华-U跌6.24%，收盘报26.74元，换手率10.49%，成交量28.16万手，成交额7.69亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为36.45亿元，最新净值3.5442，较上一交易日上涨1.65%，近一年上涨43.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"eda91c147052074b3c51088682d35767","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900020821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"gpt_icon":0},{"id":"2574313483","title":"诺诚健华-U跌6.24%，太平洋一个月前给出“买入”评级，目标价32.22元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574313483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574313483?lang=zh_cn&edition=full","pubTime":"2025-10-09 16:38","pubTimestamp":1759999116,"startTime":"0","endTime":"0","summary":"今日诺诚健华-U跌6.24%，收盘报26.74元。2025年8月29日，太平洋研究员周豫,戎晓婕发布了对诺诚健华的研报《收入增长强劲，关注奥布替尼国际化进程及海外BTKi催化》，该研报对诺诚健华给出“买入”评级，认为其目标价为32.22元，研报发布时股价为27.92元，预期涨幅为15.40%。此外，开源证券研究员余汝意,余克清,汪晋，长城国瑞证券研究员胡晨曦,魏钰琪近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900020818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","601099","688428"],"gpt_icon":0},{"id":"1146091822","title":"Zenas BioPharma Inc.新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计2026年启动一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146091822","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146091822?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:06","pubTimestamp":1759914392,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.的新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计将于2026年开始一期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO","688428","BK0239"],"gpt_icon":0},{"id":"1121287790","title":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1121287790","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121287790?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:00","pubTimestamp":1759914020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","ZBIO","BK0239","BK4139"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764962508144,"stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":0.0465},{"period":"3month","weight":-0.1281},{"period":"6month","weight":0.0175},{"period":"1year","weight":0.7246},{"period":"ytd","weight":1.035}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18800人(较上一季度增加Infinity%)","perCapita":"14274股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}